NASD · Healthcare · Biotechnology · USA
Ideaya Biosciences Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Ideaya Biosciences is a precision medicine oncology company developing targeted therapies for cancer by combining small-molecule drug discovery with biomarker validation. Its pipeline spans four therapeutic areas including darovasertib for uveal melanoma, antibody-drug conjugate combinations, MTAP pathway programs, and next generation treatments, supported through collaborations with pharmaceutical partners.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Ideaya Biosciences Inc stock.
Overvalued: intrinsic value $6.00 per share, market price $27.40, margin of safety -356.5% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $6.00; the price of $27.40 is 357% above that value.
17 more funds hold it; the full list is part of the paid plan.
79 more in this industry show a wider margin of safety.
IDYA is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $6.00; the price of $27.40 is 357% above that value.
$6.00 per share (as of the 2026-11-17 close), against a market price of $27.40. That is a margin of safety of -356.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.